PubRank

Howard L McLeod

Author PubWeight™ 266.93‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005 8.77
2 Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med 2003 7.23
3 Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004 5.12
4 Genomics and drug response. N Engl J Med 2011 4.35
5 Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 2007 3.86
6 UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007 3.85
7 A high-resolution map of segmental DNA copy number variation in the mouse genome. PLoS Genet 2006 3.24
8 Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA 2005 3.16
9 Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004 2.64
10 Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol 2011 2.47
11 Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci U S A 2004 2.37
12 CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 2009 2.32
13 Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost 2005 2.25
14 CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 2005 2.11
15 Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 2009 2.10
16 PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 2005 2.09
17 Pharmacogenomics: challenges and opportunities. Ann Intern Med 2006 1.96
18 Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 2009 1.95
19 Genomic medicine: a decade of successes, challenges, and opportunities. Sci Transl Med 2013 1.89
20 Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 2006 1.82
21 Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 2008 1.81
22 Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005 1.75
23 Knockdown of RNA binding protein musashi-1 leads to tumor regression in vivo. Gastroenterology 2008 1.68
24 Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 2009 1.61
25 A mouse-based strategy for cyclophosphamide pharmacogenomic discovery. J Appl Physiol (1985) 2003 1.55
26 Pyrosequencing of clinically relevant polymorphisms. Methods Mol Biol 2005 1.52
27 A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 2012 1.50
28 Pharmacogenomic discovery approaches: will the real genes please stand up? J Clin Oncol 2005 1.49
29 wuHMM: a robust algorithm to detect DNA copy number variation using long oligonucleotide microarray data. Nucleic Acids Res 2008 1.48
30 Pharmacogenomics of cancer chemotherapy-induced toxicity. J Support Oncol 2007 1.46
31 Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst 2012 1.46
32 Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 2003 1.42
33 Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer 2003 1.41
34 Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer 2014 1.39
35 Comment on "A frameshift mutation and alternate splicing in human brain generate a functional form of the pseudogene cytochrome P4502d7 that demethylates codeine to morphine", J Biol Chem 279: 27383-27389. Drug Metab Dispos 2005 1.38
36 Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 2003 1.36
37 CANDID: a flexible method for prioritizing candidate genes for complex human traits. Genet Epidemiol 2008 1.36
38 Pharmacogenomic characterization of US FDA-approved cytotoxic drugs. Pharmacogenomics 2011 1.34
39 Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008 1.33
40 Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol 2009 1.32
41 Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. Cancer Res 2006 1.31
42 Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 2002 1.31
43 Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst 2010 1.30
44 Pharmacogenomics: from bedside to clinical practice. Hum Mol Genet 2006 1.28
45 Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum 2006 1.27
46 PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics 2011 1.27
47 A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res 2011 1.26
48 Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov 2008 1.24
49 CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat 2012 1.23
50 A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT. Pharmacogenet Genomics 2012 1.23
51 Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol Sci 2009 1.21
52 Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer 2007 1.21
53 Tamoxifen and CYP2D6: a contradiction of data. Oncologist 2012 1.21
54 Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin Cancer Res 2008 1.20
55 Genetic variation in the B-type natiuretic peptide pathway affects BNP levels. Cardiovasc Drugs Ther 2007 1.18
56 Analysis of key cell-cycle checkpoint proteins in colorectal tumours. J Pathol 2002 1.17
57 PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet Genomics 2011 1.16
58 ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res 2004 1.16
59 PromoLign: a database for upstream region analysis and SNPs. Hum Mutat 2004 1.15
60 Cancer pharmacogenomics: current and future applications. Biochim Biophys Acta 2003 1.15
61 Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther 2004 1.13
62 Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 2005 1.13
63 Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. J Mol Diagn 2009 1.12
64 PolyMAPr: programs for polymorphism database mining, annotation, and functional analysis. Hum Mutat 2005 1.12
65 Polymorphism discovery in 51 chemotherapy pathway genes. Hum Mol Genet 2005 1.09
66 Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics 2004 1.09
67 Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin Cancer Res 2004 1.09
68 Pharmacogenomic genome-wide association studies: lessons learned thus far. Pharmacogenomics 2009 1.08
69 Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes. Pharmacogenet Genomics 2008 1.07
70 Distribution of ITPA P32T alleles in multiple world populations. J Hum Genet 2004 1.07
71 Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics 2009 1.07
72 The kinetics and tissue distribution of protein transduction in mice. Eur J Pharm Sci 2006 1.06
73 SNP databases and pharmacogenetics: great start, but a long way to go. Hum Mutat 2002 1.05
74 Association of thymidylate synthase variants with 5-fluorouracil cytotoxicity. Pharmacogenet Genomics 2009 1.05
75 The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective. Clin Cancer Res 2006 1.05
76 A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin Pharmacol Ther 2004 1.04
77 Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenet Genomics 2013 1.03
78 Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother 2010 1.03
79 Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer. Clin Cancer Res 2005 1.02
80 Characterizing genetic variants for clinical action. Am J Med Genet C Semin Med Genet 2014 1.02
81 A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol 2010 1.01
82 The candidate oncogene ZNF217 is frequently amplified in colon cancer. J Pathol 2004 1.01
83 A health services research agenda for cellular, molecular and genomic technologies in cancer care. Public Health Genomics 2009 1.01
84 Concordance of pharmacogenetic markers in germline and colorectal tumor DNA. Pharmacogenomics 2005 1.00
85 Pharmacogenetics and oncology treatment for breast cancer. Expert Opin Pharmacother 2007 1.00
86 Implementation of a pharmacogenomics service in a community pharmacy. J Am Pharm Assoc (2003) 2014 1.00
87 Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines. Pharmacogenomics 2014 1.00
88 Identification and replication of loci involved in camptothecin-induced cytotoxicity using CEPH pedigrees. PLoS One 2011 1.00
89 Beta-2 adrenergic receptor genotypes and haplotypes in different ethnic groups. Int J Mol Med 2005 1.00
90 Gene expression profiling of the irinotecan pathway in colorectal cancer. Clin Cancer Res 2005 1.00
91 Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer Res 2008 0.99
92 Ability of whole-genome SNP arrays to capture 'must have' pharmacogenomic variants. Pharmacogenomics 2008 0.99
93 CYP3A4 and CYP3A5 genotyping by Pyrosequencing. BMC Med Genet 2005 0.99
94 Genomic profiling in CEPH cell lines distinguishes between the camptothecins and indenoisoquinolines. Mol Cancer Ther 2011 0.98
95 Economic opportunities and challenges for pharmacogenomics. Annu Rev Pharmacol Toxicol 2010 0.97
96 Defining the opportunity for pharmacogenetic intervention in primary care. Pharmacogenomics 2006 0.97
97 Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers. Pharmacogenomics 2008 0.97
98 Differential expression of the AP-1 transcription factor family members in human colorectal epithelial and neuroendocrine neoplasms. Am J Clin Pathol 2005 0.96
99 Multivariate methods and software for association mapping in dose-response genome-wide association studies. BioData Min 2012 0.96
100 Copy number variants in pharmacogenetic genes. Trends Mol Med 2011 0.96
101 Implications of genome-wide association studies in cancer therapeutics. Br J Clin Pharmacol 2013 0.96
102 Genetic basis of drug metabolism. Am J Health Syst Pharm 2002 0.95
103 Identification of NR1I2 genetic variation using resequencing. Eur J Clin Pharmacol 2007 0.95
104 Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancer. Hum Mutat 2013 0.94
105 Cancer pharmacogenomics: DNA genotyping and gene expression profiling to identify molecular determinants of chemosensitivity. Drug Metab Rev 2008 0.94
106 Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma. J Clin Oncol 2011 0.94
107 Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application. J Pathol 2010 0.94
108 Ferredoxin reductase: pharmacogenomic assessment in colorectal cancer. Cancer Res 2003 0.94
109 A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 2004 0.93
110 Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors. Mol Cancer Ther 2005 0.93
111 Genetic strategies to individualize supportive care. J Clin Oncol 2002 0.93
112 Preemptive pharmacogenetic testing: insufficient data equal unsatisfactory guidance. Ann Intern Med 2011 0.93
113 The pharmacogenetics of coumarin therapy. Pharmacogenomics 2005 0.93
114 DNA repair pathway profiling and microsatellite instability in colorectal cancer. Clin Cancer Res 2006 0.92
115 Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity. J Hum Genet 2013 0.92
116 Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity. Clin Cancer Res 2013 0.91
117 Current pharmacogenomic studies on hERG potassium channels. Trends Mol Med 2013 0.91
118 A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. J Thorac Oncol 2006 0.91
119 Simple and rapid docetaxel assay in plasma by protein precipitation and high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004 0.91
120 Use of pharmacogenetics to guide warfarin therapy. Drugs Today (Barc) 2004 0.90
121 A novel duplication type of CYP2A6 gene in African-American population. Drug Metab Dispos 2007 0.90
122 The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. Oncol Rep 2011 0.90
123 Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases. Hum Pathol 2002 0.90
124 Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice. Mamm Genome 2011 0.89
125 Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. Oncologist 2012 0.89
126 A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity. Biochem Pharmacol 2005 0.89
127 Using germline genotype in cancer pharmacogenetic studies. Pharmacogenomics 2009 0.89
128 Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 2004 0.89
129 Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy. Pharmacogenomics 2012 0.89
130 Aromatase gene polymorphisms are associated with survival among patients with cardiovascular disease in a sex-specific manner. PLoS One 2010 0.89
131 Genotypes associated with myocardial infarction risk are more common in African Americans than in European Americans. J Am Coll Cardiol 2004 0.88
132 CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncol Rep 2002 0.88
133 Pharmacogenetics: using DNA to optimize drug therapy. Am Fam Physician 2007 0.88
134 Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks. Cancer Chemother Pharmacol 2006 0.88
135 Association of eleven common, low-penetrance colorectal cancer susceptibility genetic variants at six risk loci with clinical outcome. PLoS One 2012 0.88
136 Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clin Cancer Res 2006 0.87
137 Murine pharmacogenomics: using the mouse to understand the genetics of drug therapy. Pharmacogenomics 2002 0.87
138 Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial. Pharmacogenomics 2013 0.87
139 A mouse model for developing treatment for secondary liver tumors. Int J Oncol 2005 0.86
140 Global pharmacogenetics: giving the genome to the masses. Pharmacogenomics 2006 0.86
141 Drug pathways: moving beyond single gene pharmacogenetics. Pharmacogenomics 2004 0.86
142 Pharmacogenomic contribution to drug response. Cancer J 2011 0.86
143 Genome-wide association studies: powerful tools for improving drug safety and efficacy. Pharmacogenomics 2009 0.86
144 Vascular endothelial growth factor pathway. Pharmacogenet Genomics 2010 0.86
145 Pharmacogenomics: the influence of genomic variation on drug response. Curr Top Med Chem 2004 0.85
146 The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics 2013 0.85
147 Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis. Pharmacogenomics 2004 0.85
148 Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia. Saudi Med J 2004 0.85
149 Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report. Oncology (Williston Park) 2003 0.85
150 Altered expression of TFF-1 and CES-2 in Barrett's Esophagus and associated adenocarcinomas. Neoplasia 2005 0.85
151 Personalizing medicine in geriatric oncology. J Clin Oncol 2014 0.85
152 Genome-wide studies in pharmacogenomics: harnessing the power of extreme phenotypes. Pharmacogenomics 2013 0.85
153 Comprehensive evaluation of carboxylesterase-2 expression in normal human tissues using tissue array analysis. Appl Immunohistochem Mol Morphol 2002 0.85
154 New developments in the epidemiology of cancer prognosis: traditional and molecular predictors of treatment response and survival. Cancer Epidemiol Biomarkers Prev 2006 0.84
155 Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy. Eur J Cancer 2010 0.84
156 Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians. Pharmacogenomics 2011 0.84
157 Systems pharmacology assessment of the 5-fluorouracil pathway. Pharmacogenomics 2011 0.84
158 Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 2006 0.84
159 Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells. PeerJ 2013 0.83
160 Connexin37 (GJA4) genotype predicts survival after an acute coronary syndrome. Am Heart J 2007 0.83
161 ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer. Clin Cancer Res 2006 0.83
162 CEPH individuals are representative of the European American population: implications for pharmacogenetics. Pharmacogenomics 2005 0.83
163 Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer. Pharmacogenet Genomics 2009 0.83
164 Pharmacogenetics goes 3D. Nat Genet 2005 0.83
165 Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis. Oncol Rep 2002 0.83
166 Detection of the G>C SNP and rare mutations in the 28-bp repeat of TYMS using gel-based capillary electrophoresis. Pharmacogenomics 2010 0.83
167 Effect of grapefruit juice intake on etoposide bioavailability. Eur J Clin Pharmacol 2002 0.83
168 Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase. Clin Chem 2003 0.83
169 A comparison of DMET Plus microarray and genome-wide technologies by assessing population substructure. Pharmacogenet Genomics 2016 0.82
170 Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity. Pharmacogenomics 2013 0.82
171 Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients. Invest New Drugs 2004 0.82
172 Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy. Breast Cancer Res Treat 2014 0.82
173 Challenges of implementing pharmacogenetics in the critical care environment. Nat Rev Drug Discov 2004 0.82
174 Genomics: applications in mechanism elucidation. Adv Drug Deliv Rev 2008 0.81
175 Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044). Am J Clin Oncol 2007 0.81
176 Pharmacogenetics of alkylator-associated acute myeloid leukemia. Pharmacogenomics 2006 0.81
177 Pharmacogenetic analysis of clinically relevant genetic polymorphisms. Methods Mol Med 2003 0.81
178 Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes. Invest New Drugs 2006 0.81
179 Interaction between PPARA genotype and beta-blocker treatment influences clinical outcomes following acute coronary syndromes. Pharmacogenomics 2008 0.81
180 Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. Breast Cancer Res Treat 2013 0.81
181 PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics 2015 0.81
182 Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new. J Card Fail 2012 0.81
183 Pharmacogenetics and rational drug use around the world. Pharmacogenomics 2011 0.81
184 Differentially expressed genes in human peripheral blood as potential markers for statin response. J Mol Med (Berl) 2011 0.80
185 A PPARα promoter variant impairs ERR-dependent transactivation and decreases mortality after acute coronary ischemia in patients with diabetes. PLoS One 2010 0.80
186 DNA methylotype analysis in colorectal cancer. Oncol Rep 2008 0.80
187 Making pharmacogenetic testing a reality in a community pharmacy. J Am Pharm Assoc (2003) 2012 0.80
188 Clinical Implications of Opioid Pharmacogenomics in Patients With Cancer. Cancer Control 2015 0.79
189 UGT1A and irinotecan toxicity: keeping it in the family. J Clin Oncol 2009 0.79
190 Novel human CYP2A6 alleles confound gene deletion analysis. FEBS Lett 2004 0.79
191 Evaluation of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy: Is there a need for a more rational design? Eur J Cancer 2004 0.79
192 Pharmacogenomic assessment of Mexican and Peruvian populations. Pharmacogenomics 2015 0.79
193 Frequency of compound genotypes associated with beta-blocker efficacy in congestive heart failure. Pharmacogenomics 2004 0.79
194 Nevirapine hypersensitivity reaction: will the real HLA please stand up? Curr Opin Mol Ther 2009 0.79
195 The pharmacogenetics of statin therapy: when the body aches, the mind will follow. J Am Coll Cardiol 2009 0.79
196 Irinotecan pharmacogenetics: is it time to intervene? J Clin Oncol 2004 0.79
197 A mixture model approach in gene-gene and gene-environmental interactions for binary phenotypes. J Biopharm Stat 2008 0.78
198 VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians. Thromb Haemost 2013 0.78
199 Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. Pharmacogenomics 2009 0.78
200 Pharmacokinetics after endovascular lung perfusion with Cisplatin. J Vasc Interv Radiol 2006 0.78
201 Epigenetic perspectives on cancer chemotherapy response. Pharmacogenomics 2014 0.78
202 Using genome-wide mapping in the mouse to identify genes that influence drug response. Trends Pharmacol Sci 2003 0.78
203 Novel tagging SNP rs1495741 and 2-SNPs (rs1041983 and rs1801280) yield a high prediction of the NAT2 genotype in HapMap samples. Pharmacogenet Genomics 2012 0.78
204 Gastric cancer pharmacogenetics: progress or old tripe? Pharmacogenomics 2013 0.78
205 Colorectal cancer cell lines lack the molecular heterogeneity of clinical colorectal tumors. Clin Colorectal Cancer 2010 0.78
206 Clopidogrel pharmacogenetics: promising steps towards patient care? Arterioscler Thromb Vasc Biol 2006 0.77
207 Should screening for DPD deficiency be mandatory before 5-FU exposure? Onkologie 2004 0.77
208 Assessing the utility of whole genome amplified DNA as a template for DMET Plus array. Clin Chem Lab Med 2012 0.77
209 Pharmacogenetics of breast cancer therapies. Breast 2009 0.77
210 Race does not explain genetic heterogeneity in pharmacogenomic pathways. Pharmacogenomics 2008 0.77
211 Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety. Trends Pharmacol Sci 2006 0.77
212 Will we ever be ready for blood level-guided therapy? J Clin Oncol 2008 0.77
213 Applying the genome to national drug formulary policy in the developing world. Pharmacogenomics 2010 0.77
214 Analysis of variation in mouse TPMT genotype, expression and activity. Pharmacogenetics 2004 0.77
215 Clinically relevant cancer biomarkers and pharmacogenetic assays. J Oncol Pharm Pract 2013 0.77
216 Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy. Pharmacogenomics 2013 0.77
217 Primum non nocere: adverse drug events must be taken seriously. Pharmacogenomics 2007 0.77
218 Genomewide analysis of inherited variation associated with phosphorylation of PI3K/AKT/mTOR signaling proteins. PLoS One 2011 0.77
219 Relationship between red blood cell thiopurine methyltransferase activity and myelotoxicity in dogs receiving azathioprine. J Vet Intern Med 2004 0.77
220 Pharmacogenetic influences on treatment response and toxicity in colorectal cancer. Semin Oncol 2005 0.76
221 Pharmacogenetics and pediatric cancer. Cancer J 2005 0.76
222 Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity. Drug Metab Dispos 2005 0.76
223 Applications of genomic tools to colorectal cancer therapeutics. Curr Opin Mol Ther 2008 0.76
224 Beta2-adrenergic receptor genotype predicts survival: implications and future directions. J Cardiovasc Nurs 2007 0.76
225 Predictive Factors for Response and Toxicity in Chemotherapy: Pharmacogenomics. Semin Colon Rectal Surg 2008 0.75
226 Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics. BMC Res Notes 2014 0.75
227 Methotrexate and long-term treatment of rheumatic disease: comment on the article by Kremer. Arthritis Rheum 2005 0.75
228 Untapped resources for pharmacogenomic discovery in psychiatry. Curr Opin Mol Ther 2008 0.75
229 Thymidine phosphorylase and capecitabine: a predictive marker for therapy selection? J Clin Oncol 2006 0.75
230 Pharmacokinetic study of infusional valspodar. J Clin Pharmacol 2002 0.75
231 RNA expression of the molecular signature genes for metastasis in colorectal cancer. Oncol Rep 2011 0.75
232 Drug pathways: one gene is not enough. Curr Opin Mol Ther 2007 0.75
233 Length and somatic mosaicism of CAG and GGN repeats in the androgen receptor gene and the risk of prostate cancer in men with benign prostatic hyperplasia. Ann Saudi Med 2004 0.75
234 Recent advances in the pharmacogenetics of cancer chemotherapy. Curr Opin Mol Ther 2002 0.75
235 Enabling pharmacogenomic clinical trials through sampling. Pharmacogenomics 2010 0.75
236 Candidate gene selection in pharmacogenomics: biology leads the way. Pharmacogenomics 2004 0.75
237 Molecular therapeutics: are we making progress? Curr Opin Mol Ther 2003 0.75
238 Institutional profile. UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care. Pharmacogenomics 2010 0.75
239 Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment. Pharmacogenet Genomics 2017 0.75
240 Small inhibitory RNA--a tool for credentialing candidate genes. Pharmacogenomics 2005 0.75
241 Systems pharmacogenomics in yeast. Pharmacogenomics 2006 0.75
242 Endovascular lung perfusion using high-dose cisplatin: uptake and DNA adduct formation in an animal model. Oncol Rep 2004 0.75
243 Caution with beta1-adrenergic receptor genotyping. Clin Pharmacol Ther 2004 0.75